Bayer Pre-Tax Income 2010-2024 | BAYRY

Bayer pre-tax income from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Bayer Annual Pre-Tax Income
(Millions of US $)
2023 $-1,754
2022 $4,920
2021 $2,421
2020 $-19,705
2019 $3,226
2018 $2,738
2017 $5,173
2016 $6,515
2015 $5,824
2014 $6,015
2013 $5,588
2012 $4,177
2011 $4,684
2010 $2,285
2009 $2,608
Bayer Quarterly Pre-Tax Income
(Millions of US $)
2024-06-30 $-1,695
2024-03-31 $2,813
2023-12-31 $1,841
2023-09-30 $-4,677
2023-06-30 $-1,716
2023-03-31 $2,797
2022-12-31 $695
2022-09-30 $605
2022-06-30 $-557
2022-03-31 $4,177
2021-12-31 $1,762
2021-09-30 $229
2021-06-30 $-2,868
2021-03-31 $3,297
2020-12-31 $1,436
2020-09-30 $-11,000
2020-06-30 $-12,178
2020-03-31 $2,038
2019-12-31 $-287
2019-09-30 $1,152
2019-06-30 $505
2019-03-31 $1,856
2018-12-31 $-5,843
2018-09-30 $4,354
2018-06-30 $1,227
2018-03-31 $2,999
2017-12-31 $-41
2017-09-30 $1,158
2017-06-30 $1,920
2017-03-31 $2,137
2016-12-31 $528
2016-09-30 $1,697
2016-06-30 $2,060
2016-03-31 $2,228
2015-12-31 $738
2015-09-30 $1,430
2015-06-30 $1,710
2015-03-31 $1,946
2014-12-31 $152
2014-09-30 $1,425
2014-06-30 $1,783
2014-03-31 $2,655
2013-12-31 $798
2013-09-30 $1,315
2013-06-30 $1,387
2013-03-31 $2,088
2012-12-31 $726
2012-09-30 $833
2012-06-30 $704
2012-03-31 $1,914
2011-12-31 $581
2011-09-30 $1,239
2011-06-30 $1,586
2011-03-31 $1,278
2010-12-31 $-357
2010-09-30 $373
2010-06-30 $949
2010-03-31 $1,320
2009-12-31 $230
2009-09-30 $549
2009-06-30 $993
2009-03-31 $836
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $861.209B 99.68
Novo Nordisk (NVO) Denmark $526.522B 40.18
Johnson & Johnson (JNJ) United States $391.972B 15.90
AbbVie (ABBV) United States $329.494B 17.43
Merck (MRK) United States $269.339B 16.33
AstraZeneca (AZN) United Kingdom $240.110B 21.39
Novartis AG (NVS) Switzerland $236.552B 16.44
Pfizer (PFE) United States $163.938B 21.43
Sanofi (SNY) $136.164B 12.87
Innoviva (INVA) United States $1.242B 6.89